SCHEDULE: Vanguard Discloses 6.74% Stake in Xeris Biopharma

The Vanguard Group has filed an amended Schedule 13G, reporting a 6.74% beneficial ownership stake in Xeris Biopharma Holdings Inc.

Summary

• The Vanguard Group reported beneficial ownership of 11,186,677 shares of Xeris Biopharma Holdings Inc. common stock.
• This ownership represents 6.74% of the class of securities.
• Vanguard holds sole voting power over 0 shares and shared voting power over 1,339,227 shares.
• Vanguard holds sole dispositive power over 0 shares and shared dispositive power over 11,186,677 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026, and will no longer perform portfolio management services or administer proxy voting directly, with subsidiaries expected to report beneficial ownership separately.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure. While a 13G is a passive filing, the significant stake by a major institutional investor like Vanguard can be seen as a positive indicator of institutional interest and market liquidity for Xeris Biopharma.

Positives

• The disclosure of a significant 6.74% stake by a major institutional investor like The Vanguard Group indicates a degree of institutional confidence and liquidity in Xeris Biopharma Holdings Inc. stock.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Xeris Biopharma Holdings Inc.'s future performance or operations.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors, indicating their ownership stakes. The presence of a large, passive investor like Vanguard often signals a company's inclusion in various index funds or broad market portfolios, providing a baseline of institutional interest.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional holder, which can contribute to market stability and liquidity for Xeris Biopharma's stock.

Key Dates

Recommendation

A seasoned investor would interpret this Schedule 13G filing as confirmation of significant institutional ownership by The Vanguard Group. While this indicates a baseline of institutional interest and inclusion in various funds, it does not provide new fundamental information about Xeris Biopharma's operations or financial performance to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, acknowledging the stable institutional presence without suggesting immediate action based solely on this ownership disclosure.

Keywords

Xeris Biopharma Holdings Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biopharma